Diagnostyka S.a. · GPW:DIA
Diagnostyka — FY2025 Earnings Presentation
19 slides from Diagnostyka's earnings presentation, Apr 21, 2026
Slide 1: Financial results of the Diagnostyka Group for 2025
Financial results of the Diagnostyka Group for 2025 21 April 2026
Slide 2: Presenters
Presenters: Jakub Swadźba Bartosz Cieślicki President of the Management Board, Deputy Chief Financial Officer Chief Executive Officer (CEO)
Slide 3: Key developments in 2025
Diagnosty! Key developments in 2025
Slide 4: 2025 at a glance: Financial highlights
2025 at a glance Financial highlights Group revenue Net profit attributable to Test volume owners of the Parent 174.4 million PLN 2,410.5 PLN 251.6 (up 8.1% y/y) million million (up 23.6% y/y) (up 12.7% y/y) Proposed dividend per share Recurring EBITDA¹ from the Company’s 2025 net profit PLN 586.4 m
Slide 5: Key developments in 2025: network, tests, IT, M&A
Expanding network Growing test menu IT and digital Continued M&A Public-health capabilities partnerships New state-of-the- Ongoing art laboratories Introduction of development of 10 acquisitions Development of the opened 94 the xLAB in laboratory Moje Zdrowie in Rzeszów new tests laboratory system d
Slide 6: Financial performance
Diagnosty! Financial performance
Slide 7: Consistent growth track record
Consistent growth track record PLN 2,410 million in 2025 Covid nCovid Revenue from contracts with customers (PLN million) 2,410 CAGR 2011–2025: 1,950 1,843 ~24% 1,588 1,436 1,138 806 1,585 694 580 1,284 494 1,127 421 361 779 311 263 123 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 202
Slide 8: Continued strong year-on-year revenue growth
Continued strong year-on-year revenue growth Revenue from contracts with customers (PLN million) MLT: +17.7% Revenue mix: +23.6% + Strong revenue growth of +22.4% y/y in Q4 +22.4% 2,410.5 2025 (of which MLT +16.7%) and +23.6% y/y 2024 for 2025 (of which MLT +17.7%). 1,950.1 123.5 612.3 618.3 505.2 7
Slide 9: Revenue growth driven by both volume and price
Revenue growth driven by both volume and price Test volume (million) Volume mix +5.5% +8.1% + Increase in tests volume: 2024 B2C +5.5% in Q4 2025 (including +5.2% in MLT) 40.2 43.0 42.5 161.3 174.4 0.149 0.058 0.590 and +8.1% in 2025 (including +7.8% in MLT) 0.058 0.171 15.5% 42.8 42.3 161.2 173.8 +
Slide 10: Operating expenses breakdown
Operating expenses breakdown Operating expenses (PLN million) + Both in 2025 and in Q4 2025 alone, operating expenses Increase in operating 25.7% 24.7% grew year on year at a faster rate than revenue from expenses (%): contracts with customers, mainly due to: Increase in revenue from 22.4% 23.6% con
Slide 11: Recurring EBITDA at PLN 586.4 million, up 15.3% y/y
Recurring EBITDA at PLN 586.4 million, up 15.3% y/y Recurring EBITDA (PLN million) Recurring EBITDA + The Q4 2024 comparable benefited from a PLN +11.5 million 24.8% 24.9% 19.4% 26.1% 24.3% margin (%): remeasurement gain (fair value remeasurement of shares in certain diagnostic imaging entities on o
Slide 12: PLN 251.6 million net profit attributable to owners of the Parent
PLN 251.6 million net profit attributable to owners of the Parent Change Change Change Q4 2024 Q4 2025 y/y (%) y/y 2024 2025 Change y/y (%) y/y Key drivers of the change in net profit in 2025: Recurring EBITDA 125.1 120.1 -5.0 -4.0% 508.7 586.4 77.7 15.3% + Year-on-year increase in depreciation and
Slide 13: Robust cash flow supporting the Group's further growth
Robust cash flow supporting the Group's further growth Free cash flow (PLN million) Capex (PLN million) Capex excl. FCF/EBITDA 85.2% 83.9% 99.3% 85.3% 92.6% 7.4% 8.9% 13.0% 6.8% 8.5% M&A/revenue +26.9% 287.1 541.2 108.9 108.9 234.9 82.3 +15.3% 426.3 28.4 71.8 102.2 71.7 127.6 119.3 17.6 Capex 103.4
Slide 14: Net debt and working capital under control
Net debt and working capital under control + Net working capital increased by PLN 24.7 million year on year as at the end of 2025. The increase in NWC was driven, among other factors, by a PLN 35.5 million rise in receivables and a temporary PLN 23.3 million increase in inventories, mainly related t
Slide 15: 2026 Outlook for the Diagnostyka Group
2026 Outlook for the Diagnostyka Group Revenue from contracts with low/mid teens % y/y growth customers Average price per test high single digit % y/y growth Test volume low/mid single digit % y/y growth Recurring EBITDA margin close to 2025 Capex excl. M&A PLN 170-220 million M&A capex PLN 50-100 m
Slide 16: Appendices
Appendices
Slide 17: Condensed consolidated statements of comprehensive income and financial position
Full-year condensed consolidated statement of Full-year condensed consolidated statement of financial position (PLN thousand) comprehensive income (PLN thousand) As at As at As at As at 2025 2024 Change (%) Q4 2025 Q4 2024 Change (%) ASSETS Change (%) EQUITY AND LIABILITIES Change (%) 31 Dec 2025 31
Slide 18: Full-year condensed consolidated statement of cash flows
Full-year condensed consolidated statement of cash flows (PLN thousand) 2025 2024 2025 2024 Profit (loss) before tax 316,882 291,194 Cash flows from financing activities Adjustments to profit before tax: 278,202 197,457 Non-controlling interests' contributions to capital increases at subsidiaries 6,
Slide 19: Contact
Contact Michał Błasiński Investor Relations Director michal.blasinski@diag.pl Disclaimer This presentation (the “Presentation”) has been prepared by Diagnostyka S.A. (“Diagnostyka”) to share selected information about the Diagnostyka Group (“Diagnostyka Group”) with shareholders, analysts, business